These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38691665)

  • 41. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
    Xu X; Shen D; Gao Y; Zhou Q; Ni Y; Meng H; Shi H; Le W; Chen S; Chen S
    Transl Neurodegener; 2021 Aug; 10(1):29. PubMed ID: 34372914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.
    Johnson SA; Fang T; De Marchi F; Neel D; Van Weehaeghe D; Berry JD; Paganoni S
    Drugs; 2022 Sep; 82(13):1367-1388. PubMed ID: 36121612
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Update on Antioxidant Therapy with Edaravone: Expanding Applications in Neurodegenerative Diseases.
    Yamashita T; Abe K
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474192
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
    Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S
    Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550
    [TBL] [Abstract][Full Text] [Related]  

  • 45.
    Palumbo JM; Hubble J; Apple S; Takei K; Tsuda K; Liu S; Zhang J; Agnese W
    Amyotroph Lateral Scler Frontotemporal Degener; 2019 Aug; 20(5-6):421-431. PubMed ID: 30982356
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19.
    Al-Chalabi A; Chiò A; Merrill C; Oster G; Bornheimer R; Agnese W; Apple S
    J Neurol Neurosurg Psychiatry; 2021 Feb; 92(2):165-171. PubMed ID: 33109706
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
    Noto Y; Shibuya K; Vucic S; Kiernan MC
    Expert Rev Neurother; 2016 Oct; 16(10):1147-54. PubMed ID: 27314534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis.
    Dyer AM; Smith A
    Drug Des Devel Ther; 2017; 11():59-64. PubMed ID: 28053507
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical trials in amyotrophic lateral sclerosis.
    McDermott CJ
    Curr Opin Neurol; 2019 Oct; 32(5):758-763. PubMed ID: 31335338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury.
    Shakkour Z; Issa H; Ismail H; Ashekyan O; Habashy KJ; Nasrallah L; Jourdi H; Hamade E; Mondello S; Sabra M; Zibara K; Kobeissy F
    Curr Med Chem; 2021; 28(12):2369-2391. PubMed ID: 32787753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone.
    Han HJ; Shin HY; Choi YC; Kim SM; Kim SW
    Redox Rep; 2022 Dec; 27(1):79-84. PubMed ID: 35296219
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis.
    Cho H; Shukla S
    Pharmaceuticals (Basel); 2020 Dec; 14(1):. PubMed ID: 33396271
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials.
    Barp A; Gerardi F; Lizio A; Sansone VA; Lunetta C
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):145-164. PubMed ID: 32456491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants.
    Shimizu H; Nishimura Y; Shiide Y; Akimoto M; Matsuda H; Kato Y; Hirai M
    Clin Ther; 2022 Dec; 44(12):1552-1565. PubMed ID: 36376130
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study.
    Shimizu H; Nishimura Y; Shiide Y; Ueda M; Yokota S; Kato Y; Hirai M
    Clin Pharmacol Drug Dev; 2023 Jan; 12(1):77-84. PubMed ID: 36225132
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Study protocol of RESCUE-ALS: A Phase 2,
    Vucic S; Kiernan MC; Menon P; Huynh W; Rynders A; Ho KS; Glanzman R; Hotchkin MT
    BMJ Open; 2021 Jan; 11(1):e041479. PubMed ID: 33431491
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone.
    Kakimoto A; Ishizaki M; Ueyama H; Maeda Y; Ueda M
    Medicine (Baltimore); 2021 May; 100(21):e26127. PubMed ID: 34032759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies.
    Kalin A; Medina-Paraiso E; Ishizaki K; Kim A; Zhang Y; Saita T; Wasaki M
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):71-79. PubMed ID: 28872919
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.
    Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
    Muscle Nerve; 2022 Nov; 66(5):583-592. PubMed ID: 36054038
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review.
    Neupane P; Thada PK; Singh P; Faisal AR; Rai N; Poudel P; Waleed MS; Quinonez J; Ruxmohan S; Jain E
    Cureus; 2023 Jan; 15(1):e33746. PubMed ID: 36788871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.